IL4R
Interleukin-4 receptor subunit alpha
As of the edition of 20 October 2026, IL4R (interleukin-4 receptor subunit alpha, UniProt P24394) has 13 drugs tested at it and 22 companies on the list, 5 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P24394
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 10
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways; Ear, nose and throat; Cancer; Blood and lymph; Digestive system
- Registered trials of its drugs
- 319
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 8 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dupilumab | Marketed | Phase 4 | Ends 2031 |
| Stapokibart | Active | Phase 4 | none listed |
| SHR-1819 | Active | Phase 3 | none listed |
| Cintredekin besudotox | Stopped | Phase 3 | none listed |
| Rademikibart | Active | Phase 3 | none listed |
| GR1802 | Active | Phase 3 | none listed |
| AK120 | Active | Phase 3 | none listed |
| IBI3002 | Active | Phase 2 | none listed |
| Elarekibep | Stopped | Phase 2 | none listed |
| BBT002 | Active | Phase 2 | none listed |
| Bizaxofusp | Went quiet | Phase 2 | none listed |
| LQ036 | Active | Phase 2 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 1 |
| Engaged | 15 |
| Undetermined | 1 |
| Total on the list | 22 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Sanofi | Route B |
| Amgen | Route A |
The other 19 companies at IL4R
In the product22 companies in all; 19 are not named here, and no score is.
See the 22 companies at IL4R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.